• Perphenazine: Dopamine D2 Antagonist Workflows

  2026-08-15

  Perphenazine supports practical studies spanning dopamine signaling, mitochondrial injury, opioid tolerance suppression, and host-directed antibacterial research. This guide connects mechanism-driven assay design with formulation, controls, and troubleshooting strategies for more interpretable results.

• Prednisolone, ERAD, and Translational Signal Design

  2026-08-15

  Prednisolone is more than a routine corticosteroid control: it can help translational researchers define how glucocorticoid receptor-driven state changes influence inflammation, immunity, and membrane-protein biology. When interpreted alongside the 2026 development of ERAD-engaging chimeras, it also clarifies a crucial experimental distinction between changing cellular signaling and selectively eliminating a target protein. This article presents a practical framework for combining both perspectives without conflating Prednisolone pharmacology with ERAD-mediated degradation.

• L-Glutathione Reduced: Redox Workflow Guide

  2026-08-14

  L-Glutathione Reduced supports controlled redox perturbation, oxidative-stress rescue experiments, and GST affinity elution without introducing an ethanol or DMSO vehicle. This practical guide connects reduced glutathione handling to GOT1-focused pancreatic cancer assays, metabolic profiling, and reproducible troubleshooting.

• Irinotecan Assays: From Prodrug to Readout

  2026-08-14

  Irinotecan and CPT-11 assays are most informative when prodrug activation, DNA damage, apoptosis, and exposure timing are analyzed together. This evidence-centered guide translates product data and a key pharmacology review into practical colorectal cancer research decisions.

• AZD0156 Workflow for ATM Kinase Inhibition

  2026-08-13

  Build a selective ATM kinase inhibition workflow around AZD0156, from solvent handling and cellular target engagement to DNA damage combination studies. The approach combines orthogonal pharmacology with phosphoproteomic and metabolic follow-up assays to distinguish genuine pathway modulation from nonspecific cytotoxicity.

• Phenothiazines, ROS, and Autophagy in Macrophages

  2026-08-13

  The reference study identifies phenothiazines as host-directed therapy candidates that strengthen macrophage defense against intracellular bacteria through coordinated reactive oxygen species production, lysosomal activation, and autophagy. Pharmacological inhibition of autophagy or ROS reduced the antibacterial effect, while perphenazine improved infection-associated tissue outcomes in a Salmonella Typhimurium model, providing a mechanistic basis for further investigation.

• Tamoxifen in Gut Inflammation and CreER Models

  2026-08-12

  Tamoxifen is more than a selective estrogen receptor modulator: in inducible mouse genetics, it can shape how neuroimmune and epithelial phenotypes are interpreted. This guide connects Tamoxifen CreER-mediated gene knockout design with a recent intestinal inflammation study and practical assay controls.

• JXY Reprograms Macrophages in Colitis-Associated CRC

  2026-08-12

  The reference study shows that Jiedu Xiaozheng Yin limits colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-like phenotype through TLR4-associated signaling. Its combination of orthotopic disease modeling, macrophage phenotyping, phagocytosis assays, and pathway antagonism provides a useful framework for studying how complex interventions reshape the tumor immune microenvironment.

• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-08-11

  The 2026 reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that connects trophoblast ferroptosis with defective syncytialization in preeclampsia. Its evidence supports a mechanistic model in which increased O-GlcNAc modification stabilizes HUWE1, promotes TfR1 ubiquitination and degradation, limits iron uptake, and improves placental and pregnancy-related outcomes in experimental models.

• Cycloastragenol Limits Glucocorticoid Bone Loss

  2026-08-10

  This in vivo study shows that cycloastragenol reduced femoral-head necrosis and trabecular bone loss in a methylprednisolone-induced rat model of glucocorticoid-induced osteonecrosis. Its central contribution is to connect structural and vascular protection with suppression of osteoclast-associated signaling, supporting further investigation of osteoclast control as a hip-preservation strategy.

• Roxadustat, HIF–GATA1 Signaling, and Erythroleukemia

  2026-08-09

  The reference study shows that roxadustat promotes erythroid differentiation in HEL and K562 erythroleukemia cells through an HIF-α/GATA1 regulatory axis, with HIF-2α acting as the principal mediator of the drug response. Its combination results further indicate cell-model-dependent synergy with ruxolitinib or imatinib, providing a mechanistic framework for studying hypoxia, differentiation, and kinase signaling in myeloid malignancy models.

• Cepharanthine in Endometriosis: Organoid and In Vivo Evidenc

  2026-08-08

  A 2026 study evaluated Cepharanthine across immortalized stromal cells, patient-derived endometriotic cells, endometrial organoids, and a murine lesion model. The findings connect reduced lesion growth with G0/G1 arrest, DNA damage, impaired DNA repair, and mitochondrial apoptosis, while also illustrating the value of organoids for preclinical endometriosis research.

• ABT-263 (Navitoclax) for Apoptosis Workflows

  2026-08-07

  ABT-263 (Navitoclax) provides a practical way to test Bcl-2 family dependence, mitochondrial priming, and caspase-linked cell death in cancer models. This guide combines assay-ready handling advice with a metabolism-informed workflow inspired by hydride transfer complex research.

• Faropenem Sodium: Mechanistic Insights for Translational Res

  2026-08-07

  This article explores Faropenem sodium’s unique mechanistic profile as a penem antibiotic, bridging transporter biology, broad-spectrum antimicrobial action, and translational research design. By integrating molecular insights, comparative efficacy, and practical workflow guidance, it delivers strategic recommendations for researchers tackling antibiotic resistance and infection modeling.

• Mildronate-Derived Lipidoids Minimize mRNA Vaccine Inflammat

  2026-08-06

  A recent ACS Nano study demonstrates that mildronate-derived cationic lipidoids allow for efficient mRNA vaccine delivery with significantly reduced inflammatory side effects compared to conventional lipid nanoparticles. This innovation addresses a critical barrier in the clinical translation of mRNA vaccines, offering a path toward safer immunogen research and therapeutic applications.

454 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page